ORM-15341
Selleck Chemicals
SKU:E2850-5MG
Couldn't load pickup availability

ORM-15341 is an antagonist of Androgen Receptor used in studies of Hormone Signaling. It is especially relevant in cancer and endocrinology models, where defined compound exposure can be linked to ligand-dependent transcriptional programs and endocrine regulation.
By blocking Androgen Receptor, ORM-15341 can be used to examine ligand-dependent transcriptional programs and endocrine regulation. The nuclear receptor annotation adds relevance to reporter-gene, receptor-binding, and transcriptional assays, together with downstream-response mapping in the same experimental setting. In cancer and endocrinology models, these readouts can be combined with viability, reporter, localization, biochemical conversion, or morphology endpoints to refine experimental interpretation.
Research Applications
- Target-focused assays involving Androgen Receptor
- Pathway perturbation studies connected to Hormone Signaling
- Receptor-blockade and ligand-competition studies
- Reporter-gene, receptor-binding, and transcriptional assays
Overall, ORM-15341 is appropriate when a defined chemical perturbant is needed to connect Androgen Receptor with measurable biochemical, transcriptional, electrophysiological, imaging, or phenotypic readouts in cancer and endocrinology models. This profile is suited to mechanistic follow-up, comparative profiling, and assay optimization under defined exposure conditions.
- Targets:
- Androgen Receptor
- Target Class:
- Nuclear Receptor
- Pathways:
- Hormone Signaling
- Research Area:
- Cancer • Endocrinology
- CAS No.:
- 1297537-33-7
- Molecular Weight:
- 396.83
- Formula:
- C₁₉H₁₇ClN₆O₂
- Storage Temperature:
- -20°C
For Research Use Only. Not intended for diagnostic or therapeutic use.
Products may be subject to intellectual property rights.
The purchase of this product does not grant any license for commercial use, manufacturing, or clinical applications. The user is responsible for ensuring compliance with applicable laws and third-party rights.